TGFB1 and endometrial cancer: IL-6 and TGF-β1 treatments of endometrial cancer cell lines were demonstrated to affect a decrease in epithelial marker (E cadherin) and an increase in mesenchymal markers (Twist, Snail, N-cadherin) [37, 50, 55].